首页 > 最新文献

Breast disease最新文献

英文 中文
FOXP3 regulatory T cells on prognosis of breast cancer. FOXP3调节性T细胞对乳腺癌预后的影响。
Pub Date : 2023-01-01 DOI: 10.3233/BD-239002
Andi Nilawati Usman, Mardiana Ahmad, Andi Wardihan Sinrang, Sartini Natsir, A B Takko, Andi Ariyandy, Ilhamuddin Ilhamuddin, Athira Rinandha Eragradini, Intan Idiana Hasan, Sabarisah Hasyim

Background: FOXP3 Tregs have been found in breast cancer patients, both humoral and tumor. Survival or prognosis of breast cancer patients seems to correlate with the increase and decrease in FOXP3 Treg.

Objectives: This review aims to provide insights regarding the FOXP3 Tregs involved and their mechanisms in breast cancer prognosis.

Methods: The literature study method is used from primary and secondary libraries. The library search used online-based search instruments such as NCBI-PubMed, Google Scholar, and Elsevier. The data obtained were then arranged according to the framework, data on the relationship between FOXP3 Regulatory T Cells and breast cancer, and writing a journal review was carried out according to the given format. Regulators (Tregs) can inhibit anti-tumor immunity and promote tumor growth. Tregs also play a role in inhibiting cytotoxic T lymphocyte cells by inhibiting the release of granules from CD8+, where CD8+ is important in killing tumor cells. FOXP3 is a Treg-specific biomarker and plays an important role in the development and function of Tregs.

Results: Studies on the presence of FOXP3+ Tregs in tumors have shown controversial results. Studies in some tumors reported the presence of FOXP3+, indicating a poor prognosis, whereas studies in other tumors found that FOXP3+ correlated with a good prognosis.

Conclusion: Regulatory T lymphocytes and TILs in invasive breast carcinoma are still not established. Therefore, further research on the Effect of FOXP3 expression of regulatory T lymphocytes on breast cancer is still important.

背景:FOXP3 Tregs已在乳腺癌患者中发现,包括体液和肿瘤。乳腺癌患者的生存或预后似乎与FOXP3 Treg的升高或降低有关。目的:本综述旨在为FOXP3 Tregs在乳腺癌预后中的作用及其机制提供新的见解。方法:采用文献研究法,检索中小学图书馆资料。图书馆搜索使用了基于在线的搜索工具,如NCBI-PubMed、Google Scholar和Elsevier。然后将获得的数据按照框架进行整理,FOXP3调节性T细胞与乳腺癌关系的数据,并按照给定的格式撰写期刊综述。Tregs具有抑制抗肿瘤免疫、促进肿瘤生长的作用。Tregs还通过抑制CD8+颗粒的释放来抑制细胞毒性T淋巴细胞,其中CD8+在杀死肿瘤细胞中起重要作用。FOXP3是treg特异性生物标志物,在treg的发育和功能中起重要作用。结果:关于FOXP3+ Tregs在肿瘤中的存在的研究显示出有争议的结果。在一些肿瘤研究中报道FOXP3+的存在,提示预后不良,而在其他肿瘤研究中发现FOXP3+与预后良好相关。结论:在浸润性乳腺癌中,调节性T淋巴细胞与TILs的关系尚不明确。因此,进一步研究调节性T淋巴细胞FOXP3表达对乳腺癌的影响仍具有重要意义。
{"title":"FOXP3 regulatory T cells on prognosis of breast cancer.","authors":"Andi Nilawati Usman,&nbsp;Mardiana Ahmad,&nbsp;Andi Wardihan Sinrang,&nbsp;Sartini Natsir,&nbsp;A B Takko,&nbsp;Andi Ariyandy,&nbsp;Ilhamuddin Ilhamuddin,&nbsp;Athira Rinandha Eragradini,&nbsp;Intan Idiana Hasan,&nbsp;Sabarisah Hasyim","doi":"10.3233/BD-239002","DOIUrl":"https://doi.org/10.3233/BD-239002","url":null,"abstract":"<p><strong>Background: </strong>FOXP3 Tregs have been found in breast cancer patients, both humoral and tumor. Survival or prognosis of breast cancer patients seems to correlate with the increase and decrease in FOXP3 Treg.</p><p><strong>Objectives: </strong>This review aims to provide insights regarding the FOXP3 Tregs involved and their mechanisms in breast cancer prognosis.</p><p><strong>Methods: </strong>The literature study method is used from primary and secondary libraries. The library search used online-based search instruments such as NCBI-PubMed, Google Scholar, and Elsevier. The data obtained were then arranged according to the framework, data on the relationship between FOXP3 Regulatory T Cells and breast cancer, and writing a journal review was carried out according to the given format. Regulators (Tregs) can inhibit anti-tumor immunity and promote tumor growth. Tregs also play a role in inhibiting cytotoxic T lymphocyte cells by inhibiting the release of granules from CD8+, where CD8+ is important in killing tumor cells. FOXP3 is a Treg-specific biomarker and plays an important role in the development and function of Tregs.</p><p><strong>Results: </strong>Studies on the presence of FOXP3+ Tregs in tumors have shown controversial results. Studies in some tumors reported the presence of FOXP3+, indicating a poor prognosis, whereas studies in other tumors found that FOXP3+ correlated with a good prognosis.</p><p><strong>Conclusion: </strong>Regulatory T lymphocytes and TILs in invasive breast carcinoma are still not established. Therefore, further research on the Effect of FOXP3 expression of regulatory T lymphocytes on breast cancer is still important.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9829517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Complications of severe breast deformities after a silicone injection over 20-year and a successful surgical treatment. 严重乳房畸形的并发症后硅胶注射超过20年和成功的手术治疗。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230021
Hoang Thanh Tuan, Nguyen Anh Ngoc, Luu Dang Ai, Nguyen Van Luat

Breast deformities caused by silicone injections affect aesthetic results and cause irreversible complications in patients. In the treatment, it is necessary to entirely remove silicone particles and infiltrated and fibrous breast tissues. The maximal preservation of healthy breast tissues is also critical. This report presents a case of severe breast deformities as complications 20 years after silicone injections at an unreputable aesthetic center. During the surgery, the authors separately removed fluid (silicone) masses and reconstructed mammary glandular tissues. Breast reconstruction was performed by the anchor breast lift along with the functional preservation of the nipple-areola complex and the superomedial pedicle. The surgery entirely addressed complications after injecting a large amount of silicone. 6 months postoperatively, the surgical outcomes were satisfactory. The surgical excision should be done to remove silicone-infiltrated tissues as much as possible before the reconstructive surgery. The combination of radical surgical excision and reconstructive surgery using the anchor breast lift as a single-stage procedure brought good aesthetic results.

硅胶注射导致的乳房畸形影响美容效果,并给患者带来不可逆转的并发症。在治疗中,有必要完全去除硅酮颗粒和浸润性纤维性乳房组织。最大限度地保存健康的乳腺组织也是至关重要的。本报告提出了一个病例严重的乳房畸形并发症后,硅胶注射在一个不知名的美容中心20年。在手术中,作者分别切除了液体(硅胶)肿块并重建了乳腺组织。乳房重建采用锚式乳房提升术,同时保留乳头乳晕复合体和内侧上蒂的功能。手术完全解决了注射大量硅胶后的并发症。术后6个月,手术效果满意。在重建手术前,手术切除应尽可能地去除硅渗透组织。根治性手术切除与锚式乳房提升单期重建手术相结合,取得了良好的美容效果。
{"title":"Complications of severe breast deformities after a silicone injection over 20-year and a successful surgical treatment.","authors":"Hoang Thanh Tuan,&nbsp;Nguyen Anh Ngoc,&nbsp;Luu Dang Ai,&nbsp;Nguyen Van Luat","doi":"10.3233/BD-230021","DOIUrl":"https://doi.org/10.3233/BD-230021","url":null,"abstract":"<p><p>Breast deformities caused by silicone injections affect aesthetic results and cause irreversible complications in patients. In the treatment, it is necessary to entirely remove silicone particles and infiltrated and fibrous breast tissues. The maximal preservation of healthy breast tissues is also critical. This report presents a case of severe breast deformities as complications 20 years after silicone injections at an unreputable aesthetic center. During the surgery, the authors separately removed fluid (silicone) masses and reconstructed mammary glandular tissues. Breast reconstruction was performed by the anchor breast lift along with the functional preservation of the nipple-areola complex and the superomedial pedicle. The surgery entirely addressed complications after injecting a large amount of silicone. 6 months postoperatively, the surgical outcomes were satisfactory. The surgical excision should be done to remove silicone-infiltrated tissues as much as possible before the reconstructive surgery. The combination of radical surgical excision and reconstructive surgery using the anchor breast lift as a single-stage procedure brought good aesthetic results.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10465685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of DROSHA rs6877842, rs642321 and rs10719 polymorphisms with increased susceptibility to breast cancer: A case-control study with genotype and haplotype analysis. DROSHA rs6877842、rs642321和rs10719多态性与乳腺癌易感性增加的关联:一项基于基因型和单倍型分析的病例对照研究
Pub Date : 2023-01-01 DOI: 10.3233/BD-220026
Setareh Taghipour Kamalabad, Zahra Zamanzadeh, Halimeh Rezaei, Maryam Tabatabaeian, Morteza Abkar

Background: Multiple lines of evidence suggest that single nucleotide polymorphisms (SNPs) in genes encoding components of the microRNA processing machinery may underlie susceptibility to various human diseases, including cancer.

Objective: The present study aimed to investigate whether rs6877842, rs642321 and rs10719 SNPs of DROSHA, a key component of the miRNA biogenesis pathway, are associated with increased risk of breast cancer.

Methods: A total of 100 patients diagnosed with breast cancer and 100 healthy women were included. Following extraction of DNA, genotyping was performed by tetra primer- amplification refractory mutation system-PCR (T-ARMS-PCR) technique. Under the co-dominant, dominant and recessive inheritance models, the association between DROSHA SNPs and breast cancer risk was determined by logistic regression analysis. The association of DROSHA SNPs with patients' clinicopathological parameters was assessed. Also, haplotype analysis was performed to evaluate the combined effect of DROSHA SNPs on breast cancer risk.

Results: We observed a statistically significant association between DROSHA rs642321 polymorphism and breast cancer susceptibility (P < 0.05). Under the dominant inheritance model, DROSHA rs642321 polymorphism was significantly associated with increased risk of breast cancer (OR: 6.091; 95% CI: 3.291-11.26; P = 0.0001). Our findings demonstrated that DROSHA rs642321 T allele can contribute to the development of breast cancer (OR: 3.125; 95% CI: 1.984-4.923; P = 0.0001). We also found that GTC and GTT haplotypes conferred significant risk for breast cancer (OR: 2.367; 95% CI: 1.453-3.856; P = 0.0001 and OR: 7.944; 95% CI: 2.073-30.43; P = 0.0001, respectively).

Conclusions: These results provide the first evidence that DROSHA rs642321 polymorphism is associated with increased risk of breast cancer. However, further studies are needed to firmly validate these findings.

背景:多种证据表明,编码microRNA加工机制成分的基因中的单核苷酸多态性(SNPs)可能是多种人类疾病(包括癌症)易感性的基础。目的:本研究旨在探讨miRNA生物发生通路关键组分DROSHA的rs6877842、rs642321和rs10719 snp是否与乳腺癌风险增加相关。方法:选取100例确诊乳腺癌患者和100例健康女性。提取DNA后,采用四引物扩增难解突变系统pcr (T-ARMS-PCR)技术进行基因分型。在共显性、显性和隐性遗传模型下,通过logistic回归分析确定DROSHA snp与乳腺癌风险的相关性。评估DROSHA snp与患者临床病理参数的关系。此外,我们还进行了单倍型分析,以评估DROSHA snp对乳腺癌风险的综合影响。结果:我们观察到DROSHA rs642321多态性与乳腺癌易感性之间具有统计学意义的相关性(P)。结论:这些结果首次提供了DROSHA rs642321多态性与乳腺癌风险增加相关的证据。然而,需要进一步的研究来证实这些发现。
{"title":"Association of DROSHA rs6877842, rs642321 and rs10719 polymorphisms with increased susceptibility to breast cancer: A case-control study with genotype and haplotype analysis.","authors":"Setareh Taghipour Kamalabad,&nbsp;Zahra Zamanzadeh,&nbsp;Halimeh Rezaei,&nbsp;Maryam Tabatabaeian,&nbsp;Morteza Abkar","doi":"10.3233/BD-220026","DOIUrl":"https://doi.org/10.3233/BD-220026","url":null,"abstract":"<p><strong>Background: </strong>Multiple lines of evidence suggest that single nucleotide polymorphisms (SNPs) in genes encoding components of the microRNA processing machinery may underlie susceptibility to various human diseases, including cancer.</p><p><strong>Objective: </strong>The present study aimed to investigate whether rs6877842, rs642321 and rs10719 SNPs of DROSHA, a key component of the miRNA biogenesis pathway, are associated with increased risk of breast cancer.</p><p><strong>Methods: </strong>A total of 100 patients diagnosed with breast cancer and 100 healthy women were included. Following extraction of DNA, genotyping was performed by tetra primer- amplification refractory mutation system-PCR (T-ARMS-PCR) technique. Under the co-dominant, dominant and recessive inheritance models, the association between DROSHA SNPs and breast cancer risk was determined by logistic regression analysis. The association of DROSHA SNPs with patients' clinicopathological parameters was assessed. Also, haplotype analysis was performed to evaluate the combined effect of DROSHA SNPs on breast cancer risk.</p><p><strong>Results: </strong>We observed a statistically significant association between DROSHA rs642321 polymorphism and breast cancer susceptibility (P < 0.05). Under the dominant inheritance model, DROSHA rs642321 polymorphism was significantly associated with increased risk of breast cancer (OR: 6.091; 95% CI: 3.291-11.26; P = 0.0001). Our findings demonstrated that DROSHA rs642321 T allele can contribute to the development of breast cancer (OR: 3.125; 95% CI: 1.984-4.923; P = 0.0001). We also found that GTC and GTT haplotypes conferred significant risk for breast cancer (OR: 2.367; 95% CI: 1.453-3.856; P = 0.0001 and OR: 7.944; 95% CI: 2.073-30.43; P = 0.0001, respectively).</p><p><strong>Conclusions: </strong>These results provide the first evidence that DROSHA rs642321 polymorphism is associated with increased risk of breast cancer. However, further studies are needed to firmly validate these findings.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9157815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of HMGCR expression in combination therapy of simvastatin and FAC treated locally advanced breast cancer patients. HMGCR表达在辛伐他汀联合FAC治疗局部晚期乳腺癌中的作用
Pub Date : 2023-01-01 DOI: 10.3233/BD-220021
Erwin Danil Yulian, Nurjati Chairani Siregar, Bajuadji Sudijono, Lie Rebecca Yen Hwei

Objective: Several studies have shown the role of statin added to the patient's chemotherapy regimen and the role of Hydroxymethylglutaryl-CoA Reductase (HMGCR) expression in predicting breast cancer patient outcomes. In our previous study, adding statins improved clinical and pathological responses in LABC patients. Furthermore, we planned to study statin's role as a combination to neoadjuvant chemotherapy (NAC) in treating locally advanced breast cancers on the basis of HMGCR expression. Moreover, we aimed to study the association between the patients' clinicopathological characteristics and HMGCR expression.

Methods: This study is a randomized, double-blinded, placebo-controlled trial in two health centers in Indonesia. Each patient enrolled with written informed consent and then randomized to receive either simvastatin 40 mg/day or a placebo, combined with the fluorouracil, adriamycin, and cyclophosphamide (FAC) NAC.

Results: HMGCR was associated with low staging and normal serum cholesterol in the high Ki67 level group (p = 0.042 and p = 0.021, respectively). The pre-and post-chemotherapy tumor sizes are significantly correlated in two groups (HMGCR negative expression, p = 0.000 and HMGCR moderate expression, p = 0.001) with a more considerable average decrease in tumor size compared to HMGCR strong expression group.

Conclusion: Statin therapy might work better in HMGCR-negative or low-expression tumors, although HGMCR expression is associated with better clinical parameters in our study.

目的:几项研究表明,他汀类药物在患者化疗方案中的作用以及羟甲基戊二酰辅酶a还原酶(HMGCR)表达在预测乳腺癌患者预后中的作用。在我们之前的研究中,他汀类药物可以改善LABC患者的临床和病理反应。此外,我们计划在HMGCR表达的基础上研究他汀类药物联合新辅助化疗(NAC)治疗局部晚期乳腺癌的作用。此外,我们旨在研究患者的临床病理特征与HMGCR表达的关系。方法:本研究是一项随机、双盲、安慰剂对照试验,在印度尼西亚的两个卫生中心进行。每位患者均获得书面知情同意,然后随机接受辛伐他汀40mg /天或安慰剂,联合氟尿嘧啶、阿霉素和环磷酰胺(FAC) NAC。结果:高Ki67组HMGCR与低分期、正常血清胆固醇相关(p = 0.042、p = 0.021)。两组患者化疗前后肿瘤大小有显著相关性(HMGCR阴性表达,p = 0.000, HMGCR中度表达,p = 0.001),且肿瘤大小的平均降幅较HMGCR强表达组明显。结论:他汀类药物治疗hmgcr阴性或低表达肿瘤可能效果更好,尽管在我们的研究中HGMCR表达与更好的临床参数相关。
{"title":"The role of HMGCR expression in combination therapy of simvastatin and FAC treated locally advanced breast cancer patients.","authors":"Erwin Danil Yulian,&nbsp;Nurjati Chairani Siregar,&nbsp;Bajuadji Sudijono,&nbsp;Lie Rebecca Yen Hwei","doi":"10.3233/BD-220021","DOIUrl":"https://doi.org/10.3233/BD-220021","url":null,"abstract":"<p><strong>Objective: </strong>Several studies have shown the role of statin added to the patient's chemotherapy regimen and the role of Hydroxymethylglutaryl-CoA Reductase (HMGCR) expression in predicting breast cancer patient outcomes. In our previous study, adding statins improved clinical and pathological responses in LABC patients. Furthermore, we planned to study statin's role as a combination to neoadjuvant chemotherapy (NAC) in treating locally advanced breast cancers on the basis of HMGCR expression. Moreover, we aimed to study the association between the patients' clinicopathological characteristics and HMGCR expression.</p><p><strong>Methods: </strong>This study is a randomized, double-blinded, placebo-controlled trial in two health centers in Indonesia. Each patient enrolled with written informed consent and then randomized to receive either simvastatin 40 mg/day or a placebo, combined with the fluorouracil, adriamycin, and cyclophosphamide (FAC) NAC.</p><p><strong>Results: </strong>HMGCR was associated with low staging and normal serum cholesterol in the high Ki67 level group (p = 0.042 and p = 0.021, respectively). The pre-and post-chemotherapy tumor sizes are significantly correlated in two groups (HMGCR negative expression, p = 0.000 and HMGCR moderate expression, p = 0.001) with a more considerable average decrease in tumor size compared to HMGCR strong expression group.</p><p><strong>Conclusion: </strong>Statin therapy might work better in HMGCR-negative or low-expression tumors, although HGMCR expression is associated with better clinical parameters in our study.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9154008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Machine learning analysis of breast ultrasound to classify triple negative and HER2+ breast cancer subtypes. 乳腺超声对三阴性和HER2+乳腺癌亚型的机器学习分析。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220018
Romuald Ferre, Janne Elst, Seanthan Senthilnathan, Andrew Lagree, Sami Tabbarah, Fang-I Lu, Ali Sadeghi-Naini, William T Tran, Belinda Curpen

Objectives: Early diagnosis of triple-negative (TN) and human epidermal growth factor receptor 2 positive (HER2+) breast cancer is important due to its increased risk of micrometastatic spread necessitating early treatment and for guiding targeted therapies. This study aimed to evaluate the diagnostic performance of machine learning (ML) classification of newly diagnosed breast masses into TN versus non-TN (NTN) and HER2+ versus HER2 negative (HER2-) breast cancer, using radiomic features extracted from grayscale ultrasound (US) b-mode images.

Materials and methods: A retrospective chart review identified 88 female patients who underwent diagnostic breast US imaging, had confirmation of invasive malignancy on pathology and receptor status determined on immunohistochemistry available. The patients were classified as TN, NTN, HER2+ or HER2- for ground-truth labelling. For image analysis, breast masses were manually segmented by a breast radiologist. Radiomic features were extracted per image and used for predictive modelling. Supervised ML classifiers included: logistic regression, k-nearest neighbour, and Naïve Bayes. Classification performance measures were calculated on an independent (unseen) test set. The area under the receiver operating characteristic curve (AUC), sensitivity (%), and specificity (%) were reported for each classifier.

Results: The logistic regression classifier demonstrated the highest AUC: 0.824 (sensitivity: 81.8%, specificity: 74.2%) for the TN sub-group and 0.778 (sensitivity: 71.4%, specificity: 71.6%) for the HER2 sub-group.

Conclusion: ML classifiers demonstrate high diagnostic accuracy in classifying TN versus NTN and HER2+ versus HER2- breast cancers using US images. Identification of more aggressive breast cancer subtypes early in the diagnostic process could help achieve better prognoses by prioritizing clinical referral and prompting adequate early treatment.

目的:三阴性(TN)和人表皮生长因子受体2阳性(HER2+)乳腺癌的早期诊断非常重要,因为其微转移扩散的风险增加,需要早期治疗并指导靶向治疗。本研究旨在评估机器学习(ML)分类新诊断乳腺肿块为TN与非TN (NTN), HER2+与HER2阴性(HER2-)乳腺癌的诊断性能,使用从灰度超声(US) b型图像中提取的放射学特征。材料和方法:回顾性分析88例接受乳腺超声诊断、病理证实浸润性恶性肿瘤、免疫组织化学确定受体状态的女性患者。将患者分为TN、NTN、HER2+或HER2-进行基线标记。为了进行图像分析,乳房肿块由乳房放射科医生手工分割。每张图像提取放射学特征并用于预测建模。有监督的ML分类器包括:逻辑回归、k近邻和Naïve贝叶斯。分类性能指标在独立(未见)测试集上计算。报告每个分类器的受者工作特征曲线下面积(AUC)、灵敏度(%)和特异性(%)。结果:logistic回归分类器显示,TN亚组的AUC最高,为0.824(敏感性:81.8%,特异性:74.2%);HER2亚组的AUC最高,为0.778(敏感性:71.4%,特异性:71.6%)。结论:ML分类器在使用US图像对乳腺癌进行TN与NTN、HER2+与HER2-的分类时具有较高的诊断准确性。在诊断过程的早期识别更具侵袭性的乳腺癌亚型可以通过优先考虑临床转诊和促进适当的早期治疗来帮助实现更好的预后。
{"title":"Machine learning analysis of breast ultrasound to classify triple negative and HER2+ breast cancer subtypes.","authors":"Romuald Ferre,&nbsp;Janne Elst,&nbsp;Seanthan Senthilnathan,&nbsp;Andrew Lagree,&nbsp;Sami Tabbarah,&nbsp;Fang-I Lu,&nbsp;Ali Sadeghi-Naini,&nbsp;William T Tran,&nbsp;Belinda Curpen","doi":"10.3233/BD-220018","DOIUrl":"https://doi.org/10.3233/BD-220018","url":null,"abstract":"<p><strong>Objectives: </strong>Early diagnosis of triple-negative (TN) and human epidermal growth factor receptor 2 positive (HER2+) breast cancer is important due to its increased risk of micrometastatic spread necessitating early treatment and for guiding targeted therapies. This study aimed to evaluate the diagnostic performance of machine learning (ML) classification of newly diagnosed breast masses into TN versus non-TN (NTN) and HER2+ versus HER2 negative (HER2-) breast cancer, using radiomic features extracted from grayscale ultrasound (US) b-mode images.</p><p><strong>Materials and methods: </strong>A retrospective chart review identified 88 female patients who underwent diagnostic breast US imaging, had confirmation of invasive malignancy on pathology and receptor status determined on immunohistochemistry available. The patients were classified as TN, NTN, HER2+ or HER2- for ground-truth labelling. For image analysis, breast masses were manually segmented by a breast radiologist. Radiomic features were extracted per image and used for predictive modelling. Supervised ML classifiers included: logistic regression, k-nearest neighbour, and Naïve Bayes. Classification performance measures were calculated on an independent (unseen) test set. The area under the receiver operating characteristic curve (AUC), sensitivity (%), and specificity (%) were reported for each classifier.</p><p><strong>Results: </strong>The logistic regression classifier demonstrated the highest AUC: 0.824 (sensitivity: 81.8%, specificity: 74.2%) for the TN sub-group and 0.778 (sensitivity: 71.4%, specificity: 71.6%) for the HER2 sub-group.</p><p><strong>Conclusion: </strong>ML classifiers demonstrate high diagnostic accuracy in classifying TN versus NTN and HER2+ versus HER2- breast cancers using US images. Identification of more aggressive breast cancer subtypes early in the diagnostic process could help achieve better prognoses by prioritizing clinical referral and prompting adequate early treatment.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9456332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pseudoangiomatous stromal hyperplasia of the breast: Clinical evaluation. 乳腺假性血管瘤间质增生:临床评价。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220070
Ahmet Cem Esmer, Deniz Tazeoglu, Ahmet Dag

Background: Pseudoangiomatous stromal hyperplasia is a rare benign breast stromal proliferative lesion of the breast. Clinical presentation ranges from rapidly growing mass to incidental identification in routine screening. This difference in manifestation and its rarity makes it difficult to be a standard treatment protocol. Therefore, we aimed to share our clinical experience in Pseudoangiomatous stromal hyperplasia.

Methods: The files of patients who underwent core biopsy or surgical excision due to a breast mass and resulted in pseudoangiomatous stromal hyperplasia between January 2013 and December 2021 were included in the study.

Results: 17 patients with a median age of 37 (22-68) were found Pseudoangiomatous stromal hyperplasia confirmed by surgical excision or core biopsy. Chosen treatment option was observation in 8 patients (47.1%), while surgical excision was used in 9 (52.9%) patients. The mean follow-up period was 55.24 ± 26.72 (13-102) months. None of the patients observed the Malignant transformation during the follow-up period.

Conclusion: For Pseudoangiomatous Stromal Hyperplasia of the breast, surgical excision with clean margins or close follow-up after diagnosis confirmation by tissue biopsy is sufficient. Pseudoangiomatous Stromal Hyperplasia is not a risk factor for developing breast cancer.

背景:假性血管瘤间质增生是一种罕见的乳腺良性间质增生性病变。临床表现从快速增长的肿块到在常规筛查中偶然发现。这种表现上的差异及其罕见性使其难以成为标准的治疗方案。因此,我们希望在此分享我们治疗假性血管瘤间质增生的临床经验。方法:纳入2013年1月至2021年12月期间因乳腺肿块接受核心活检或手术切除并导致假性血管瘤间质增生的患者档案。结果:17例患者中位年龄为37岁(22-68岁),经手术切除或核心活检证实为假性血管瘤间质增生。选择的治疗方案为观察8例(47.1%),手术切除9例(52.9%)。平均随访时间55.24±26.72(13-102)个月。随访期间未见恶性转化。结论:对于乳腺假性血管瘤性间质增生,经组织活检确认诊断后,行边缘清洁的手术切除或密切随访即可。假性血管瘤间质增生不是发生乳腺癌的危险因素。
{"title":"Pseudoangiomatous stromal hyperplasia of the breast: Clinical evaluation.","authors":"Ahmet Cem Esmer,&nbsp;Deniz Tazeoglu,&nbsp;Ahmet Dag","doi":"10.3233/BD-220070","DOIUrl":"https://doi.org/10.3233/BD-220070","url":null,"abstract":"<p><strong>Background: </strong>Pseudoangiomatous stromal hyperplasia is a rare benign breast stromal proliferative lesion of the breast. Clinical presentation ranges from rapidly growing mass to incidental identification in routine screening. This difference in manifestation and its rarity makes it difficult to be a standard treatment protocol. Therefore, we aimed to share our clinical experience in Pseudoangiomatous stromal hyperplasia.</p><p><strong>Methods: </strong>The files of patients who underwent core biopsy or surgical excision due to a breast mass and resulted in pseudoangiomatous stromal hyperplasia between January 2013 and December 2021 were included in the study.</p><p><strong>Results: </strong>17 patients with a median age of 37 (22-68) were found Pseudoangiomatous stromal hyperplasia confirmed by surgical excision or core biopsy. Chosen treatment option was observation in 8 patients (47.1%), while surgical excision was used in 9 (52.9%) patients. The mean follow-up period was 55.24 ± 26.72 (13-102) months. None of the patients observed the Malignant transformation during the follow-up period.</p><p><strong>Conclusion: </strong>For Pseudoangiomatous Stromal Hyperplasia of the breast, surgical excision with clean margins or close follow-up after diagnosis confirmation by tissue biopsy is sufficient. Pseudoangiomatous Stromal Hyperplasia is not a risk factor for developing breast cancer.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9311112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Observational analysis of clinical and pathological characteristics and their prognostic impact in Mexican patients with breast cancer: A multi-center study. 墨西哥癌症患者临床和病理特征及其预后影响的观察分析:一项多中心研究。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230025
Anna Gozalishvilli-Boncheva, Iván R Gonzalez-Espinoza, Abraham Castro-Ponce, Omar A Bravo-Gutiérrez, Gabriela Juárez-Salazar, Ricardo I Montes-de-Oca-Moreda, Evelyn Aguirre-Flores, Marisela Coyotl-Huexotl, Juan Orozco-Luis, Mariana Chiquillo-Domínguez, Julio C Garibay-Díaz, Jorge E Aranda-Claussen, Eric A Ponce-de-León, Sergio Sánchez-Sosa, Mónica Sabaté-Fernández, Juan C García-Reyna, Carlos Cordero-Vargas, María J González-Blanco, José M Aguilar-Priego, Norberto J Sánchez-Fernández, Carlos A Cortés-García, Laura E González-Lozada, Enrique Miguel-Cruz, Francisco J Ceja-Utrera, Maria S Hernández-Garcia, Mirielly Piña-Vazquez, Carmen Aguilar-Jiménez

Breast cancer is the most incidental and deadly neoplasm worldwide; in Mexico, very few epidemiologic reports have analyzed the pathological features and its impact on their clinical outcome. Here, we studied the relation between pathological features and the clinical presentation at diagnosis and their impact on the overall and progression-free survival of patients with breast cancer. For this purpose, we collected 199 clinical records of female patients, aged at least 18 years old (y/o), with breast cancer diagnosis confirmed by biopsy. We excluded patients with incomplete or conflicting clinical records. Afterward, we performed an analysis of overall and progression-free survival and associated risks. Our results showed an average age at diagnosis of 52 y/o (24-85), the most common features were: upper outer quadrant tumor (32%), invasive ductal carcinoma (76.8%), moderately differentiated (44.3%), early clinical stages (40.8%), asymptomatic patients (47.8%), luminal A subtype (47.8%). Median overall survival was not reached, but median progression-free survival was 32.2 months (29.75-34.64, CI 95%) associated risk were: clinical stage (p < 0.0001) symptomatic presentation (p = 0.009) and histologic grade (p = 0.02). Therefore, we concluded that symptom presence at diagnosis impacts progression-free survival, and palpable symptoms are related to an increased risk for mortality.

癌症是全世界最常见、最致命的肿瘤;在墨西哥,很少有流行病学报告分析其病理特征及其对临床结果的影响。在此,我们研究了病理特征与诊断时临床表现之间的关系,以及它们对癌症患者总体生存率和无进展生存率的影响。为此,我们收集了199例女性患者的临床记录,年龄至少为18岁(y/o),通过活组织检查确诊为乳腺癌症。我们排除了临床记录不完整或相互矛盾的患者。之后,我们对总体和无进展生存率及相关风险进行了分析。我们的结果显示,诊断时的平均年龄为52岁(24-85岁),最常见的特征是:上外象限肿瘤(32%)、浸润性导管癌(76.8%)、中分化型(44.3%)、早期临床分期(40.8%)、无症状患者(47.8%)、管腔A亚型(47.8%,但中位无进展生存期为32.2个月(29.75-34.64,CI 95%),相关风险为:临床分期(p
{"title":"Observational analysis of clinical and pathological characteristics and their prognostic impact in Mexican patients with breast cancer: A multi-center study.","authors":"Anna Gozalishvilli-Boncheva,&nbsp;Iván R Gonzalez-Espinoza,&nbsp;Abraham Castro-Ponce,&nbsp;Omar A Bravo-Gutiérrez,&nbsp;Gabriela Juárez-Salazar,&nbsp;Ricardo I Montes-de-Oca-Moreda,&nbsp;Evelyn Aguirre-Flores,&nbsp;Marisela Coyotl-Huexotl,&nbsp;Juan Orozco-Luis,&nbsp;Mariana Chiquillo-Domínguez,&nbsp;Julio C Garibay-Díaz,&nbsp;Jorge E Aranda-Claussen,&nbsp;Eric A Ponce-de-León,&nbsp;Sergio Sánchez-Sosa,&nbsp;Mónica Sabaté-Fernández,&nbsp;Juan C García-Reyna,&nbsp;Carlos Cordero-Vargas,&nbsp;María J González-Blanco,&nbsp;José M Aguilar-Priego,&nbsp;Norberto J Sánchez-Fernández,&nbsp;Carlos A Cortés-García,&nbsp;Laura E González-Lozada,&nbsp;Enrique Miguel-Cruz,&nbsp;Francisco J Ceja-Utrera,&nbsp;Maria S Hernández-Garcia,&nbsp;Mirielly Piña-Vazquez,&nbsp;Carmen Aguilar-Jiménez","doi":"10.3233/BD-230025","DOIUrl":"10.3233/BD-230025","url":null,"abstract":"<p><p>Breast cancer is the most incidental and deadly neoplasm worldwide; in Mexico, very few epidemiologic reports have analyzed the pathological features and its impact on their clinical outcome. Here, we studied the relation between pathological features and the clinical presentation at diagnosis and their impact on the overall and progression-free survival of patients with breast cancer. For this purpose, we collected 199 clinical records of female patients, aged at least 18 years old (y/o), with breast cancer diagnosis confirmed by biopsy. We excluded patients with incomplete or conflicting clinical records. Afterward, we performed an analysis of overall and progression-free survival and associated risks. Our results showed an average age at diagnosis of 52 y/o (24-85), the most common features were: upper outer quadrant tumor (32%), invasive ductal carcinoma (76.8%), moderately differentiated (44.3%), early clinical stages (40.8%), asymptomatic patients (47.8%), luminal A subtype (47.8%). Median overall survival was not reached, but median progression-free survival was 32.2 months (29.75-34.64, CI 95%) associated risk were: clinical stage (p < 0.0001) symptomatic presentation (p = 0.009) and histologic grade (p = 0.02). Therefore, we concluded that symptom presence at diagnosis impacts progression-free survival, and palpable symptoms are related to an increased risk for mortality.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41100542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical significance of Notch receptors in triple negative breast cancer. 三阴性乳腺癌中 Notch 受体的临床意义。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220041
Heer Shah, Mittal Mistry, Nupur Patel, Hemangini Vora

Background: The Notch signaling pathway is an evolutionary conserved cell signaling pathway that plays an indispensable role in essential developmental processes. Aberrant activation of Notch pathway is known to initiate wide array of diseases and cancers.

Objective: To evaluate the clinical significance of Notch receptors in Triple Negative Breast Cancer.

Methods: We evaluated the association between Notch receptors and clinicopathological parameters including disease-free survival and overall survival of one hundred TNBC patients by immunohistochemistry.

Results: Positive expression of nuclear Notch1 receptor (18%) was found be significantly correlated with positive lymph node (p = 0.009), high BR score (p = 0.02) and necrosis (p = 0.004) while cytoplasmic expression of Notch2 receptor (26%) was significantly correlated with metastasis (p = 0.05), worse DFS (p = 0.05) and poor OS (p = 0.02) in TNBC patients. Membrane (18%) and cytonuclear (3%) Notch3 expression were significantly associated with poorly differentiated tumors (p = 0.007), high BR score (p = 0.002) and necrosis (p = 0.03) respectively. However, cytoplasmic Notch3 and Notch4 expression were negatively correlated with poor prognostic factors.

Conclusions: Our data indicated that Notch receptors play a key role in promoting TNBC and mainly, Notch2 may contribute to poor prognosis of the disease. Hence, it is implicated that Notch2 may serve as a potential biomarker and therapeutic target for TNBC.

背景:Notch信号通路是一种进化保守的细胞信号通路,在重要的发育过程中发挥着不可或缺的作用。众所周知,Notch通路的异常激活会引发多种疾病和癌症:评估 Notch 受体在三阴性乳腺癌中的临床意义:方法:我们通过免疫组化方法评估了Notch受体与临床病理参数(包括100例TNBC患者的无病生存率和总生存率)之间的关系:结果:发现核Notch1受体(18%)的阳性表达与淋巴结阳性(p = 0.009)、BR评分高(p = 0.02)和坏死(p = 0.004)显著相关,而Notch2受体(26%)的胞浆表达与TNBC患者的转移(p = 0.05)、较差的DFS(p = 0.05)和较差的OS(p = 0.02)显著相关。膜(18%)和胞核(3%)Notch3的表达分别与肿瘤分化不良(p = 0.007)、BR评分高(p = 0.002)和坏死(p = 0.03)显著相关。然而,细胞质Notch3和Notch4的表达与不良预后因素呈负相关:我们的数据表明,Notch受体在促进TNBC的发展中起着关键作用,其中主要是Notch2可能会导致该病的不良预后。因此,Notch2可作为TNBC的潜在生物标志物和治疗靶点。
{"title":"Clinical significance of Notch receptors in triple negative breast cancer.","authors":"Heer Shah, Mittal Mistry, Nupur Patel, Hemangini Vora","doi":"10.3233/BD-220041","DOIUrl":"10.3233/BD-220041","url":null,"abstract":"<p><strong>Background: </strong>The Notch signaling pathway is an evolutionary conserved cell signaling pathway that plays an indispensable role in essential developmental processes. Aberrant activation of Notch pathway is known to initiate wide array of diseases and cancers.</p><p><strong>Objective: </strong>To evaluate the clinical significance of Notch receptors in Triple Negative Breast Cancer.</p><p><strong>Methods: </strong>We evaluated the association between Notch receptors and clinicopathological parameters including disease-free survival and overall survival of one hundred TNBC patients by immunohistochemistry.</p><p><strong>Results: </strong>Positive expression of nuclear Notch1 receptor (18%) was found be significantly correlated with positive lymph node (p = 0.009), high BR score (p = 0.02) and necrosis (p = 0.004) while cytoplasmic expression of Notch2 receptor (26%) was significantly correlated with metastasis (p = 0.05), worse DFS (p = 0.05) and poor OS (p = 0.02) in TNBC patients. Membrane (18%) and cytonuclear (3%) Notch3 expression were significantly associated with poorly differentiated tumors (p = 0.007), high BR score (p = 0.002) and necrosis (p = 0.03) respectively. However, cytoplasmic Notch3 and Notch4 expression were negatively correlated with poor prognostic factors.</p><p><strong>Conclusions: </strong>Our data indicated that Notch receptors play a key role in promoting TNBC and mainly, Notch2 may contribute to poor prognosis of the disease. Hence, it is implicated that Notch2 may serve as a potential biomarker and therapeutic target for TNBC.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9198934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The new potential application for Mg(II) cysteinedithiocarbamate complex with anticancer activity. 具有抗癌活性的Mg(II)半胱氨酸二硫代氨基甲酸酯配合物的新应用前景。
Pub Date : 2023-01-01 DOI: 10.3233/BD-239006
Indah Raya, Desy Kartina, Rizal Irfandi, Sandi Sufiandi, Ronald Ivan Wijaya, Prihantono Prihantono, Eid A Abdalrazaq, Mahmoud Kandeel, Andi Nilawati Usman

Objective: The new Mg(II) cysteindithiocarbamate complex drug has been synthesized by the in-situ method and tested for its anticancer activity in vitro.

Method: Mg(II) cysteindithiocarbamate complexes were characterized using Ultra Violet Visible, Infra-Red, melting points, and molar conductivity.

Results: The UV-Vis data of cysteindithiocarbamate Mg(II), shows that at 296 nm and 385 nm was occurred the electronic transitions π → π* and n → π* for CS2 and N =C =S. Whereas the IR data at wavelengths in the 393-540 cm-1 shows that there has coordinated between Mg(II) with Sulfur (S), Nitrogen (N), and Oxygen (O) atoms from cysteinedithiocarbamate ligands.

Conclusion: The cytotoxicity test results showed that the Mg complex's cytotoxicity was higher than that of the cytotoxicity of the Mg metal without ligands, which means that the Mg complex can be developed as a potential new anticancer drug.

目的:原位合成新型半胱氨酸二硫代氨基甲酸镁配合物,并进行体外抗癌活性测定。方法:采用紫外可见光谱、红外光谱、熔点、摩尔电导率等方法对半胱氨酸二硫代氨基甲酸镁配合物进行表征。结果:半胱氨酸硫代氨基甲酸酯Mg(II)的紫外可见光谱表明,CS2在296 nm和385 nm处发生π→π*和n→π*电子跃迁,n =C =S。而393 ~ 540 cm-1波段的红外数据表明,Mg(II)与半胱氨酸二硫代氨基甲酸酯配体中的硫(S)、氮(N)和氧(O)原子之间存在配位。结论:细胞毒性试验结果表明,Mg配合物的细胞毒性高于不含配体的金属Mg的细胞毒性,这意味着Mg配合物可以作为一种潜在的新型抗癌药物开发。
{"title":"The new potential application for Mg(II) cysteinedithiocarbamate complex with anticancer activity.","authors":"Indah Raya,&nbsp;Desy Kartina,&nbsp;Rizal Irfandi,&nbsp;Sandi Sufiandi,&nbsp;Ronald Ivan Wijaya,&nbsp;Prihantono Prihantono,&nbsp;Eid A Abdalrazaq,&nbsp;Mahmoud Kandeel,&nbsp;Andi Nilawati Usman","doi":"10.3233/BD-239006","DOIUrl":"https://doi.org/10.3233/BD-239006","url":null,"abstract":"<p><strong>Objective: </strong>The new Mg(II) cysteindithiocarbamate complex drug has been synthesized by the in-situ method and tested for its anticancer activity in vitro.</p><p><strong>Method: </strong>Mg(II) cysteindithiocarbamate complexes were characterized using Ultra Violet Visible, Infra-Red, melting points, and molar conductivity.</p><p><strong>Results: </strong>The UV-Vis data of cysteindithiocarbamate Mg(II), shows that at 296 nm and 385 nm was occurred the electronic transitions π → π* and n → π* for CS2 and N =C =S. Whereas the IR data at wavelengths in the 393-540 cm-1 shows that there has coordinated between Mg(II) with Sulfur (S), Nitrogen (N), and Oxygen (O) atoms from cysteinedithiocarbamate ligands.</p><p><strong>Conclusion: </strong>The cytotoxicity test results showed that the Mg complex's cytotoxicity was higher than that of the cytotoxicity of the Mg metal without ligands, which means that the Mg complex can be developed as a potential new anticancer drug.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10060043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of Fas/FasL pathway blocking on apoptosis and stemness within breast cancer tumor microenvironment (preclinical study). Fas/FasL通路阻断对乳腺癌肿瘤微环境中细胞凋亡和干细胞的影响(临床前研究)。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220077
Seham Abou Shousha, Suzan Baheeg, Hossam Ghoneim, Malak Zoheir, Mahmoud Hemida, Yasmine Shahine

Evasion of the immune system is the tumor's key strategy for its maintenance and progression. Thus, targeting the tumor microenvironment (TME) is considered one of the most promising approaches for fighting cancer, where immune cells within the TME play a vital role in immune surveillance and cancer elimination.FasL is one of the most important death ligands expressed by tumor-infiltrating lymphocytes (TILs) and plays a vital role in eliminating Fas-expressing cancer cells via Fas/FasL pathway-induced apoptosis. However, tumor cells can express elevated levels of FasL inducing apoptosis to TILs. Fas/FasL expression is linked to the maintenance of cancer stem cells (CSCs) within the TME, contributing to tumor aggressiveness, metastasis, recurrence, and chemoresistance.This study is considered the first study designed to block the overexpressed FasL on the tumor cells within TME mimicking tissue culture system using rFas molecules and supplementing the Fas enriched tissue culture system with blocked Fas - peripheral blood mononuclear cells PBMCs (using anti-Fas mAb) to protect them from tumor counterattack and augment their ability to induce tumor cell apoptosis and stemness inhibition.A significantly increased level of apoptosis and decreased expression of CD 44 (CSCs marker) was observed within the east tumor tissue culture system enriched with Fas molecules and anti-Fas treated PBMCs and the one enriched with Fas molecules only compared to the breast tumor tissues cultured alone (p < 0.001). Accordingly, we can consider the current study as a promising proposed immunotherapeutic strategy for breast cancer.

逃避免疫系统是肿瘤维持和发展的关键策略。因此,靶向肿瘤微环境(TME)被认为是最有前途的抗癌方法之一,其中TME内的免疫细胞在免疫监视和癌症消除中起着至关重要的作用。FasL是肿瘤浸润淋巴细胞(tumor-浸润淋巴细胞,til)表达的最重要的死亡配体之一,通过Fas/FasL通路诱导凋亡,在消灭表达Fas的癌细胞中起着至关重要的作用。然而,肿瘤细胞可以表达高水平的FasL诱导TILs凋亡。Fas/FasL表达与TME内肿瘤干细胞(CSCs)的维持有关,有助于肿瘤的侵袭性、转移、复发和化疗耐药。本研究被认为是第一个在TME模拟组织培养系统中,利用rFas分子阻断肿瘤细胞上过表达的FasL,并在富含Fas的组织培养系统中补充被阻断的Fas -外周血单核细胞PBMCs(使用anti-Fas mAb),以保护它们免受肿瘤的攻击,并增强其诱导肿瘤细胞凋亡和干细胞抑制的能力的研究。与单独培养的乳腺肿瘤组织相比,在富含Fas分子和抗Fas处理的PBMCs以及仅富含Fas分子的PBMCs中,细胞凋亡水平显著增加,cd44 (CSCs标志物)的表达显著降低(p
{"title":"The effect of Fas/FasL pathway blocking on apoptosis and stemness within breast cancer tumor microenvironment (preclinical study).","authors":"Seham Abou Shousha,&nbsp;Suzan Baheeg,&nbsp;Hossam Ghoneim,&nbsp;Malak Zoheir,&nbsp;Mahmoud Hemida,&nbsp;Yasmine Shahine","doi":"10.3233/BD-220077","DOIUrl":"https://doi.org/10.3233/BD-220077","url":null,"abstract":"<p><p>Evasion of the immune system is the tumor's key strategy for its maintenance and progression. Thus, targeting the tumor microenvironment (TME) is considered one of the most promising approaches for fighting cancer, where immune cells within the TME play a vital role in immune surveillance and cancer elimination.FasL is one of the most important death ligands expressed by tumor-infiltrating lymphocytes (TILs) and plays a vital role in eliminating Fas-expressing cancer cells via Fas/FasL pathway-induced apoptosis. However, tumor cells can express elevated levels of FasL inducing apoptosis to TILs. Fas/FasL expression is linked to the maintenance of cancer stem cells (CSCs) within the TME, contributing to tumor aggressiveness, metastasis, recurrence, and chemoresistance.This study is considered the first study designed to block the overexpressed FasL on the tumor cells within TME mimicking tissue culture system using rFas molecules and supplementing the Fas enriched tissue culture system with blocked Fas - peripheral blood mononuclear cells PBMCs (using anti-Fas mAb) to protect them from tumor counterattack and augment their ability to induce tumor cell apoptosis and stemness inhibition.A significantly increased level of apoptosis and decreased expression of CD 44 (CSCs marker) was observed within the east tumor tissue culture system enriched with Fas molecules and anti-Fas treated PBMCs and the one enriched with Fas molecules only compared to the breast tumor tissues cultured alone (p < 0.001). Accordingly, we can consider the current study as a promising proposed immunotherapeutic strategy for breast cancer.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9654909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Breast disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1